Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 58th American Society of Hematology (ASH) Annual Meeting & Exposition will be held in San Diego, California. The ASH Annual Meeting is the world's premier event in malignant and non-malignant hematology.

ASH 2016

03–06 December 2016 | San Diego, California

ASH 2016

03–06 December 2016 | San Diego, California

The 58th American Society of Hematology (ASH) Annual Meeting & Exposition will be held in San Diego, California. The ASH Annual Meeting is the world's premier event in malignant and non-malignant hematology.

Big data on efficacy and toxicity levels for ibrutinib in CLL 1:58
Big data on efficacy and toxicity levels for ibrutinib in CLL
George Follows • 3 Dec 2016
PHILEMON: a step closer to using MRD to guide treatment decisions in mantle cell lymphoma (MCL)? 2:01
PHILEMON: a step closer to using MRD to guide treatment decisions in mantle cell lymphoma (MCL)?
Carsten Niemann • 3 Dec 2016
The myeloma genome project and the aim to disseminate this worldwide 1:57
The myeloma genome project and the aim to disseminate this worldwide
Gareth Morgan • 3 Dec 2016
Using computational algorithms to predict the response of MDS patients to hypomethylating agents 5:47
Using computational algorithms to predict the response of MDS patients to hypomethylating agents
Aziz Nazha • 3 Dec 2016
Trial of vadastuximab talirine combined with 7+3 induction therapy for newly diagnosed AML patients 11:55
Trial of vadastuximab talirine combined with 7+3 induction therapy for newly diagnosed AML patients
Harry Erba • 3 Dec 2016
Determining the incidence & risk factors for central venous catheter related thrombosis in children 5:02
Determining the incidence & risk factors for central venous catheter related thrombosis in children
Julie Jaffray • 3 Dec 2016
Improved outcomes in leukemia, trauma settings with personalized medicine approaches 4:37
Improved outcomes in leukemia, trauma settings with personalized medicine approaches
Mikkael Sekeres • 3 Dec 2016
Naveen Pemmaraju: what to look out for at ASH 2016 2:47
Naveen Pemmaraju: what to look out for at ASH 2016
Naveen Pemmaraju • 3 Dec 2016
Targeted factor VIII delivery in hemophilia with inhibitors 6:32
Targeted factor VIII delivery in hemophilia with inhibitors
Caroline Hansen • 3 Dec 2016
MAJIC trial results: ruxolitinib compared to best available therapy for essential thrombocythemia 3:40
MAJIC trial results: ruxolitinib compared to best available therapy for essential thrombocythemia
Claire Harrison • 3 Dec 2016
MRD negative complete remissions following anti-CD22 CAR in relapsed/refractory ALL 6:57
MRD negative complete remissions following anti-CD22 CAR in relapsed/refractory ALL
Terry J. Fry • 3 Dec 2016
Novel therapies and unique delivery methods to improve treatment for bleeding crises, leukemia 5:04
Novel therapies and unique delivery methods to improve treatment for bleeding crises, leukemia
Armand Keating • 3 Dec 2016
Adeno-associated virus mediated gene transfer for hemophilia B 6:27
Adeno-associated virus mediated gene transfer for hemophilia B
Katherine A. High • 3 Dec 2016
Unmet clinical need: a low-cost, easy-to-use, portable platform for assessment of hemostasis 5:29
Unmet clinical need: a low-cost, easy-to-use, portable platform for assessment of hemostasis
Evi Stavrou • 3 Dec 2016
EURO-SKI trial: cessation of TKI treatment in CML patients with deep molecular response 6:02
EURO-SKI trial: cessation of TKI treatment in CML patients with deep molecular response
Francois-Xavier Mahon • 3 Dec 2016
Clinical challenges in chronic myeloid leukemia 5:15
Clinical challenges in chronic myeloid leukemia
Mhairi Copland • 3 Dec 2016

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals